Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alastair M Thompson

Showing results (81-90 of 195) with videos related to

Pageof 20
Sort By:
Breast Cancer Research and Treatment|June 10, 2011
Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trialSirwan Hadad, Takayuki Iwamoto, Lee Jordan, et al.
International Journal of Cancer|November 13, 2008
Seliciclib (CYC202, R-roscovitine) enhances the antitumor effect of doxorubicin in vivo in a breast cancer xenograft modelMaria Virginia C L Appleyard, Mary A O'Neill, Karen E Murray, et al.
NPJ Breast Cancer|December 10, 2020
Contralateral breast cancer risk in patients with ductal carcinoma in situ and invasive breast cancerDaniele Giardiello, Iris Kramer, Maartje J Hooning, et al.
Molecular Cancer Therapeutics|June 20, 2012
Trans,trans,trans-[PtIV(N3)2(OH)2(py)(NH3)]: a light-activated antitumor platinum complex that kills human cancer cells by an apoptosis-independent mechanismAron F Westendorf, Julie A Woods, Katharina Korpis, et al.
Breast Cancer Research : BCR|January 22, 2011
p53 mutant breast cancer patients expressing p53γ have as good a prognosis as wild-type p53 breast cancer patientsJean-Christophe Bourdon, Marie P Khoury, Alexandra Diot, et al.
Annals of Surgical Oncology|June 10, 2020
Correction to: SentimagIC: A Non-inferiority Trial Comparing Superparamagnetic Iron Oxide Versus Technetium-99m and Blue Dye in the Detection of Axillary Sentinel Nodes in Patients with Early-Stage Breast CancerMichael D Alvarado, Elizabeth A Mittendorf, Mediget Teshome, et al.
Annals of Surgical Oncology|July 13, 2019
SentimagIC: A Non-inferiority Trial Comparing Superparamagnetic Iron Oxide Versus Technetium-99m and Blue Dye in the Detection of Axillary Sentinel Nodes in Patients with Early-Stage Breast CancerMichael D Alvarado, Elizabeth A Mittendorf, Mediget Teshome, et al.
Breast Cancer Research and Treatment|February 16, 2015
Evidence for biological effects of metformin in operable breast cancer: biomarker analysis in a pre-operative window of opportunity randomized trialSirwan M Hadad, Philip Coates, Lee B Jordan, et al.
BMC Cancer|September 3, 2009
Histological evaluation of AMPK signalling in primary breast cancerSirwan M Hadad, Lee Baker, Philip R Quinlan, et al.
The Journal of Pathology. Clinical Research|October 9, 2019
∆Np63/p40 correlates with the location and phenotype of basal/mesenchymal cancer stem-like cells in human ER<sup>+</sup> and HER2<sup>+</sup> breast cancersYajing Liu, Marta Nekulova, Rudolf Nenutil, et al.
Pageof 20

Showing results (81-90 of 195) with videos related to

Sort By:
Pageof 20
Breast Cancer Research and Treatment|June 10, 2011
Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trialSirwan Hadad, Takayuki Iwamoto, Lee Jordan, et al.
International Journal of Cancer|November 13, 2008
Seliciclib (CYC202, R-roscovitine) enhances the antitumor effect of doxorubicin in vivo in a breast cancer xenograft modelMaria Virginia C L Appleyard, Mary A O'Neill, Karen E Murray, et al.
NPJ Breast Cancer|December 10, 2020
Contralateral breast cancer risk in patients with ductal carcinoma in situ and invasive breast cancerDaniele Giardiello, Iris Kramer, Maartje J Hooning, et al.
Molecular Cancer Therapeutics|June 20, 2012
Trans,trans,trans-[PtIV(N3)2(OH)2(py)(NH3)]: a light-activated antitumor platinum complex that kills human cancer cells by an apoptosis-independent mechanismAron F Westendorf, Julie A Woods, Katharina Korpis, et al.
Breast Cancer Research : BCR|January 22, 2011
p53 mutant breast cancer patients expressing p53γ have as good a prognosis as wild-type p53 breast cancer patientsJean-Christophe Bourdon, Marie P Khoury, Alexandra Diot, et al.
Annals of Surgical Oncology|June 10, 2020
Correction to: SentimagIC: A Non-inferiority Trial Comparing Superparamagnetic Iron Oxide Versus Technetium-99m and Blue Dye in the Detection of Axillary Sentinel Nodes in Patients with Early-Stage Breast CancerMichael D Alvarado, Elizabeth A Mittendorf, Mediget Teshome, et al.
Annals of Surgical Oncology|July 13, 2019
SentimagIC: A Non-inferiority Trial Comparing Superparamagnetic Iron Oxide Versus Technetium-99m and Blue Dye in the Detection of Axillary Sentinel Nodes in Patients with Early-Stage Breast CancerMichael D Alvarado, Elizabeth A Mittendorf, Mediget Teshome, et al.
Breast Cancer Research and Treatment|February 16, 2015
Evidence for biological effects of metformin in operable breast cancer: biomarker analysis in a pre-operative window of opportunity randomized trialSirwan M Hadad, Philip Coates, Lee B Jordan, et al.
BMC Cancer|September 3, 2009
Histological evaluation of AMPK signalling in primary breast cancerSirwan M Hadad, Lee Baker, Philip R Quinlan, et al.
The Journal of Pathology. Clinical Research|October 9, 2019
∆Np63/p40 correlates with the location and phenotype of basal/mesenchymal cancer stem-like cells in human ER<sup>+</sup> and HER2<sup>+</sup> breast cancersYajing Liu, Marta Nekulova, Rudolf Nenutil, et al.
Pageof 20